PMID- 32918587
OWN - NLM
STAT- MEDLINE
DCOM- 20210308
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 70
IP  - 3
DP  - 2021 Mar
TI  - Reviving up dendritic cells can run cancer immune wheel in non-small cell lung 
      cancer: a prospective two-arm study.
PG  - 733-742
LID - 10.1007/s00262-020-02704-7 [doi]
AB  - BACKGROUND AND AIM: Lung cancer is the number one cause of cancer-related deaths. 
      Dendritic cells (DCs) are heterogeneous components of innate immunity that play a 
      crucial role in the anti-tumor T cell immunity and may represent a promising 
      approach for tumor immunotherapy. In this study, we aimed to evaluate the 
      frequency of the two major subsets of DCs; plasmacytoid dendritic cells (pDCs) 
      and monocytic dendritic cells (mDCs) in non-small cell lung cancer (NCSLC) and 
      correlating them with different clinicopathologic features and survival outcomes. 
      PATIENTS AND METHODS: This study was a case-controlled one, included 50 patients 
      with denovo pathologically confirmed NSCLC and 20 healthy controls of comparable 
      age and gender. After diagnosis and staging of patients, the frequency of DCs was 
      evaluated using flow cytometry. RESULTS: We unveiled significantly reduced levels 
      of pDCs (P = 0.024), and mDCs (P = 0.013) in NSCLC patients compared to controls. 
      Furthermore, there was a significant accumulation of pDCs in non-metastatic 
      patients compared to metastatic ones (P < 0.0001), while there was no significant 
      (P = 0.6) differences in mDCs, and mDCs/pDCs ratio (P = 0.9). There was a 
      Significant negative correlation (r = - 0.3, P = 0.04) between OS and mDCs. On 
      the other hand, there was a significantly higher OS with pDCs >/= 0.82 compared to 
      patients with pDCs < 0.82, log rank Ch(2) = 12.128, P < 0.0001. CONCLUSION: 
      Despite the controversy about the prognostic role of pDCs not only in NSCLC but 
      also in other solid tumors, our study sheds light on the possible prognostic 
      impact of pDCs and mDCs on treatment outcomes of NSCLC patients.
FAU - Zahran, Asmaa M
AU  - Zahran AM
AD  - Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, 
      Assiut, 71515, Egypt.
FAU - Hetta, Helal F
AU  - Hetta HF
AUID- ORCID: 0000-0001-8541-7304
AD  - Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut 
      University, Assiut, 71515, Egypt. hettahf@ucmail.uc.edu.
AD  - Department of Internal Medicine, University of Cincinnati College of Medicine, 
      Cincinnati, OH, 45267-0595, USA. hettahf@ucmail.uc.edu.
FAU - Mansour, Shimaa
AU  - Mansour S
AD  - Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, 
      Assiut, 71515, Egypt.
FAU - Saad, Ereny S
AU  - Saad ES
AD  - Clinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, 
      71515, Egypt.
FAU - Rayan, Amal
AU  - Rayan A
AD  - Clinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, 
      71515, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20200912
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Biomarkers)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers
MH  - Carcinoma, Non-Small-Cell Lung/*immunology/mortality/pathology
MH  - Case-Control Studies
MH  - Dendritic Cells/*immunology/*metabolism
MH  - *Disease Susceptibility/immunology
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunophenotyping
MH  - Lung Neoplasms/*immunology/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
PMC - PMC10992848
OTO - NOTNLM
OT  - Dendritic cells
OT  - Non-small lung cancer
OT  - Overall survival
COIS- The authors declare that they had no conflict of interest
EDAT- 2020/09/13 06:00
MHDA- 2021/03/09 06:00
PMCR- 2020/09/12
CRDT- 2020/09/12 12:05
PHST- 2020/07/10 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/09/13 06:00 [pubmed]
PHST- 2021/03/09 06:00 [medline]
PHST- 2020/09/12 12:05 [entrez]
PHST- 2020/09/12 00:00 [pmc-release]
AID - 10.1007/s00262-020-02704-7 [pii]
AID - 2704 [pii]
AID - 10.1007/s00262-020-02704-7 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2021 Mar;70(3):733-742. doi: 
      10.1007/s00262-020-02704-7. Epub 2020 Sep 12.